XML 35 R32.htm IDEA: XBRL DOCUMENT v2.4.0.6
GENERAL (Details) (USD $)
In Thousands, unless otherwise specified
 3 Months Ended 12 Months Ended 0 Months Ended 1 Months Ended
Jun. 30, 2012
Mar. 31, 2012
Dec. 31, 2011
Sep. 30, 2011
Jun. 30, 2011
Mar. 31, 2011
Dec. 31, 2010
Sep. 30, 2010
Jun. 30, 2012
Jun. 30, 2011
Jun. 30, 2010
Jun. 19, 2011
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
Aug. 31, 2011
United Therapeutics Corporation [Member]
Licensing Agreements [Member]
GENERAL [Abstract]                          
Accumulated losses $ (65,747)       $ (50,953)       $ (65,747) $ (50,953)      
Net loss (4,135) (4,171) (1,992) (4,493) (3,725) (2,613) (2,821) (1,689) (14,794) (10,848) (7,453)    
Acquired Finite-Lived Intangible Assets [Line Items]                          
Proceeds from intangible assets                         7,000
Nonrefundable deposit on intangible asset                       5,000  
Advance payment for development costs                       2,000  
Contingent consideration receivable if certain regulatory milestones are reached                       37,500  
Maximum amount of reimbursement expenses if certain milestones reached                       $ 10,000